ISSN: 2639-2534
Authors: Alrouhayyah R* and Suslina SN
Trimetazidine, a piperazine derivative, has been in use for a long time as a safe drug in the long-term treatment of chronic ischemic disorders. The mechanism of action is basically that it partially inhibits mitochondrial fatty acid β-oxidation by blocking long-chain 3-ketoacyl-CoA thiolase and simultaneously enhances glucose oxidation, which means less oxygen consumption and increased mitochondrial efficiency by producing more adenosine triphosphate per mole of oxygen through glucose oxidation. However, as a metabolic modulator, the potency of trimetazidine has been studied to treat several diseases or disorders, which are considered to be caused by metabolic disorders. In this review, we highlight some of the studies that aimed to investigate the role of trimetazidine in treating some of these diseases, namely amyotrophic lateral sclerosis, statininduced skeletal muscle damage, and cardiomyopathy and peripheral arterial diseases, namely amyotrophic lateral sclerosis, statin-induced skeletal muscle damage, and cardiomyopathy and peripheral arterial disease associated with diabetes.
Keywords: Trimetazidine; Metabolic Agent; Angina; Diabetes; COVID-19
